Atara Biotherapeutics — Third Quarter 2026 Earnings Summary

Atara Biotherapeutics reported a net loss of $2.2 million for the third quarter of 2026, a significant improvement from the $4.3 million loss in the same period of 2025. The company's cash, cash equivalents, and short-term investments totaled $9.9 million as of September 30, 2026, which is expected to fund operations through mid-2027. Total revenues for the quarter were $1.2 million, primarily driven by commercialization activities, while research and development expenses decreased to $1.1 million. The U.S. FDA has accepted the resubmission of the Biologics License Application for tabelecleucel, with a target action date set for March 31, 2027, which could trigger a $31 million milestone payment from Pierre Fabre Laboratories upon approval.